Vertex Readies For Major Readouts, With Data Due Soon In Big Pain Market
Phase II LSR Results For Suzetrigine Due By Year End
Q3 revenue beat consensus and Vertex raised its guidance, but R&D progress was the main highlight across the cystic fibrosis, kidney disease, type 1 diabetes and, particularly, pain pipeline.
